痰热清注射液联合利奈唑胺治疗老年肺炎的疗效观察

Clinical observation of Tanreqing Injection combined with linezolid in treatment of elderly pneumonia

目的探究痰热清注射液联合利奈唑胺治疗老年肺炎的临床疗效。方法选取2014年3月—2015年3月成都市公共卫生临床医疗中心收治的老年肺炎患者180例,随机分为对照组和治疗组,每组各90例。对照组静脉滴注利奈唑胺注射液,600 mg/次,2次/d。治疗组在对照组治疗基础上给予痰热清注射液20 m L/次,加入到250 m L生理盐水中静脉滴注,1次/d。两组均连续治疗14 d。观察两组的临床疗效,同时比较两组功能独立性评定(FIM)评分、超敏C-反应蛋白(hs-CRP)、白细胞、中性粒细胞、血小板、尿氮素水平变化情况。结果治疗后,对照组和治疗组的总有效率分别为76.67%、93.33%,两组比较差异有统计学意义(P<0.05)。治疗后,两组重度依赖度患者均有明显的减少(P<0.05),轻度依赖患者均显著增多(P<0.05);治疗组治疗后重度依赖患者明显少于对照组,轻度依赖患者明显多于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者hs-CRP、白细胞和中性粒细胞均较治疗前显著降低,同组治疗前后差异有统计学意义(P<0.05);且治疗组的下降程度优于对照组,两组比较差异有统计学意义(P<0.05)。结论痰热清注射液联合利奈唑胺治疗老年肺炎具有较好的临床疗效,可降低患者hs-CRP、白细胞和中性粒细胞计数,且不良反应发生率低,具有一定的临床推广应用价值。

Objective To observe the clinical effect of Tanreqing Injection combined with linezolid in treatment of elderly pneumonia. Methods Patients（180 cases） with elderly pneumonia in Public Health Clinical Center of Chengdu from March 2014 to March 2015 were randomly divided into control and treatment groups, and each group had 90 cases. The patients in the control group were iv administered with Linezolid Injection, 600 mg/time, twice daily. The patients in the treatment group were iv administered with Tanreqing Injection on the basis of control group, 20 mL/time adding into 250 mL physiological saline, once daily. Two groups were treated for 14 d. After treatment, the efficacy was evaluated, the changes of functional independence evaluation（FIM） scores, hs-CRP, white blood cells, neutrophils, platelets and urine nitrogen in two groups were compared. Results After treatment, the efficacies in the control and treatment groups were 76.67% and 93.33%, respectively, and there was difference between two groups（P〈0.05）. After treatment, patients with severe dependence in two groups had significant reduction（P〈0.05）, while mild dependence patients were significantly increased（P〈0.05）. The severe dependence patients in treatment group were less than that in the control group, and mild dependence patients were more than that in the control group, and there was difference between two groups（P〈0.05）. After treatment, hs-CRP, white blood cells and neutrophils in two groups were significantly reduced, and the difference was statistically significant in the same group（P〈0.05）. And these indicators in treatment group improved better than those in the control group, with significant differences between two groups（P〈0.05）. Conclusion Tanreqing Injection combined with linezolid has good clinical efficacy in treatment of elderly pneumonia, and can reduce hs-CRP, white blood cells and neutrophils with low incidence of adverse reactions, which has a certain clinical application value.